Mustang Bio Stock Forecast, Price & News

-0.29 (-8.33 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $3.19
50-Day Range
MA: $3.45
52-Week Range
Now: $3.19
Volume2.42 million shs
Average Volume2.97 million shs
Market Capitalization$271.71 million
P/E RatioN/A
Dividend YieldN/A
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Mustang Bio logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MBIO
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.25 per share


Net Income$-46,390,000.00


Market Cap$271.71 million
Next Earnings Date5/10/2021 (Estimated)


Tuesday 12/15 Insider Buying Report: MBIO, DK
December 15, 2020 |
Is MBIO A Good Stock To Buy Now?
December 15, 2020 |
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
November 9, 2020 |
Fortress Biotech Inc. Registere (CNB.SG)
October 9, 2020 |
See More Headlines


Overall MarketRank

1.64 out of 5 stars

Medical Sector

334th out of 2,011 stocks

Pharmaceutical Preparations Industry

152nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.29 (-8.33 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

Is Mustang Bio a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mustang Bio stock.
View analyst ratings for Mustang Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Mustang Bio?

Wall Street analysts have given Mustang Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mustang Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Mustang Bio

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) released its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.11.
View Mustang Bio's earnings history

How has Mustang Bio's stock been impacted by Coronavirus?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBIO stock has increased by 35.7% and is now trading at $3.19.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MBIO?

4 brokerages have issued twelve-month target prices for Mustang Bio's stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate Mustang Bio's stock price to reach $11.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for Mustang Bio
or view top-rated stocks among Wall Street analysts.

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 55, Pay $60k)
  • Dr. Manuel Litchman, Pres, CEO & Director (Age 67, Pay $519.6k)
  • Mr. Brian K. Achenbach M.B.A., Sr. VP of Fin. & Corp. Controller (Age 56, Pay $302.36k)
  • Dr. Knut Niss, Chief Technology Officer
  • Ms. Debra Manning SPHR, VP of HR
  • Ms. Lynn E. Bayless, Head of Regulatory Affairs
  • Ms. Robyn M. Hunter, Corp. Sec. (Age 59)

Who are some of Mustang Bio's key competitors?

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu Biopharma (AYTU) and (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Spotlight Asset Group Inc. (0.36%). Company insiders that own Mustang Bio stock include Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends for Mustang Bio

Which major investors are buying Mustang Bio stock?

MBIO stock was purchased by a variety of institutional investors in the last quarter, including Spotlight Asset Group Inc.. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman.
View insider buying and selling activity for Mustang Bio
or or view top insider-buying stocks.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $3.19.

How much money does Mustang Bio make?

Mustang Bio has a market capitalization of $271.71 million. The company earns $-46,390,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does Mustang Bio have?

Mustang Bio employs 51 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is

Where are Mustang Bio's headquarters?

Mustang Bio is headquartered at 377 PLANTATION STREET, WORCESTER MA, 01605.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 4/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.